Show simple item record

dc.contributor.authorMirshafiey, A
dc.contributor.authorCuzzocrea, S
dc.contributor.authorRehm, BHA
dc.contributor.authorMatsuo, H
dc.date.accessioned2018-03-13T00:36:58Z
dc.date.available2018-03-13T00:36:58Z
dc.date.issued2005
dc.identifier.issn1643-3750
dc.identifier.urihttp://hdl.handle.net/10072/371054
dc.description.abstractBackground: The tolerability and the anti-inflammatory and immunosuppressiveproperties of a novel designed non-steroidal anti-inflammatory drug, M2000 (beta-D-mannuronic acid),were investigated in various experimental models. Material/Methods: The anti-inflammatory and immunosuppressiveproperties of M2000 were tested in experimental models of rheumatoid arthritis (AIA) and multiple sclerosis(EAE). Its therapeutic potency on kidney diseases was studied using experimental models of nephrosisand immune complex glomerulonephritis (ICG). Biocompatibility and pharmacotoxicology assessment of M2000was carried out using a fibrosarcoma cell line, zymography, and serum and urine determinants. Results:Data showed that oral and/or i.p. administration of M2000 significantly reduces paw edema and histopathologicalparameters in arthritic rats. The immunosuppressive property of M2000 could significantly diminish clinicalsigns and histological erosions in the EAE model. Lymph node cell proliferation assay in EAE confirmedthe immunosuppressive efficacy of the tested drug. Our findings in ICG and experimental nephrosis showedthat M2000 enables a significant decrease in proteinuria, BUN, serum creatinine and cholesterol, as wellas glomerular lesion in M2000-treated rats. Moreover, this drug inhibited MMP-2 activity. The pharmacotoxicologystudy showed that M2000 is the safest anti-inflammatory and immunosuppressive drug in comparison withdexamethasone and conventional NSAIDs tested. Additionally, M2000 had no ulcerogenic effect on the ratstomach. Conclusions: M2000 is the first novel designed NSAID with the lowest molecular weight, no gastro-nephrotoxicity,and therapeutic effects in glomerulonephritis and nephrosis and could be strongly recommended on an extensivescale as the safest drug for decreasing anti-inflammatory reactions.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherInternational Scientific Literature, Inc
dc.publisher.urihttps://www.medscimonit.com/abstract/index/idArt/202335/act/2
dc.relation.ispartofpagefromP153
dc.relation.ispartofpagetoP163
dc.relation.ispartofissue8
dc.relation.ispartofjournalMedical Science Monitor
dc.relation.ispartofvolume11
dc.subject.fieldofresearchMedical Microbiology not elsewhere classified
dc.subject.fieldofresearchMedical and Health Sciences
dc.subject.fieldofresearchcode110899
dc.subject.fieldofresearchcode11
dc.titleM2000: A revolution in pharmacology
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
dcterms.licensehttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© The Author(s) 2005. This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
gro.hasfulltextFull Text
gro.griffith.authorRehm, Bernd


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record